Literature DB >> 8401561

Hypothalamic neuropeptide Y messenger ribonucleic acid levels in pre-obese and genetically obese (fa/fa) rats; potential regulation thereof by corticotropin-releasing factor.

O B Bchini-Hooft van Huijsduijnen1, F Rohner-Jeanrenaud, B Jeanrenaud.   

Abstract

Neuropeptide Y (NPY) is a 36 amino-acid peptide. It is localized within the brain but is also present peripherally. It is a well substantiated orexigenic peptide with several other endocrine and behavioural effects. In this study NPY mRNA levels were measured, using the polymerase chain reaction amplification technique, in the hypothalamus of pre-obese (unweaned 13-day-old), young (weaned 28-day-old) and adult (11-week-old) obese fa/fa rats and compared to those of lean age-matched controls. Before weaning, pre-obese pups had the same NPY mRNA levels as controls. After weaning NPY mRNA levels were increased 2-fold in young 28-day-old and 4-fold in adult obese rats, relative to corresponding controls. When adult obese rats were intracerebroventricularly-treated with ovine corticotropin-releasing hormone (oCRF) for 7 days, they stopped gaining body weight relative to vehicle-infused obese controls. Upon measuring NPY mRNA levels in the hypothalamus of these two groups of animals, it was shown that the high NPY mRNA levels of vehicle-treated (control) obese rats were decreased by 3-fold following the intracerebroventricular oCRF administration. It is proposed that: 1) hypothalamic NPY may play a role in the establishment and maintenance of the genetic obesity syndrome of the fa/fa rat, and 2) maintenance of the genetic obesity syndrome of the fa/fa rat, and 2) hypothalamic NPY could be partly regulated by central CRF.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8401561     DOI: 10.1111/j.1365-2826.1993.tb00498.x

Source DB:  PubMed          Journal:  J Neuroendocrinol        ISSN: 0953-8194            Impact factor:   3.627


  8 in total

1.  Hypothalamic ghrelin treatment modulates NPY-but not CRH-ergic activity in adrenalectomized rats subjected to food restriction: Evidence of a novel hypothalamic ghrelin effect.

Authors:  Eduardo Spinedi; Marie-Jeanne Voirol; Chantal Verdumo; Marco Giacominni; François Pralong; Rolf C Gaillard
Journal:  Endocrine       Date:  2006-06       Impact factor: 3.633

Review 2.  Hungry for life: How the arcuate nucleus and neuropeptide Y may play a critical role in mediating the benefits of calorie restriction.

Authors:  Robin K Minor; Joy W Chang; Rafael de Cabo
Journal:  Mol Cell Endocrinol       Date:  2008-11-11       Impact factor: 4.102

Review 3.  Neuropeptide Y in normal eating and in genetic and dietary-induced obesity.

Authors:  B Beck
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-07-29       Impact factor: 6.237

Review 4.  Insulin, corticosterone and the autonomic nervous system in animal obesities: a viewpoint.

Authors:  B Jeanrenaud
Journal:  Diabetologia       Date:  1995-08       Impact factor: 10.122

5.  Adrenalectomy reduces neuropeptide Y-induced insulin release and NPY receptor expression in the rat ventromedial hypothalamus.

Authors:  T Wisialowski; R Parker; E Preston; A Sainsbury; E Kraegen; H Herzog; G Cooney
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

6.  Chronic central neuropeptide Y infusion in normal rats: status of the hypothalamo-pituitary-adrenal axis, and vagal mediation of hyperinsulinaemia.

Authors:  A Sainsbury; F Rohner-Jeanrenaud; I Cusin; K E Zakrzewska; P A Halban; R C Gaillard; B Jeanrenaud
Journal:  Diabetologia       Date:  1997-11       Impact factor: 10.122

7.  Induction and reversibility of an obesity syndrome by intracerebroventricular neuropeptide Y administration to normal rats.

Authors:  R Vettor; N Zarjevski; I Cusin; F Rohner-Jeanrenaud; B Jeanrenaud
Journal:  Diabetologia       Date:  1994-12       Impact factor: 10.122

Review 8.  Role of cytokines in AIDS wasting.

Authors:  H R Chang; A G Dulloo; B R Bistrian
Journal:  Nutrition       Date:  1998 Nov-Dec       Impact factor: 4.008

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.